Login to Your Account

Gilead Sciences, GlobeImmune Cook Up HBV Vaccine Deal

By Marie Powers
Staff Writer

Wednesday, October 26, 2011

Gilead Sciences Inc. and privately held GlobeImmune Inc. turned up the heat on an already sizzling hepatitis space by inking an exclusive worldwide license and collaboration to develop therapeutic vaccines that use Gilead's Viread (tenofovir disoproxil fumarate) and other oral therapies to treat chronic hepatitis B virus (HBV).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription